Strain amycolatopsis mediterranei - rifamycin producer in

 

(57) Abstract:

Usage: biotechnology, biosynthesis of the antibiotic rifamycin Century invention: to improve the productivity of the biosynthesis of rifamycin refined In a new strain of Amycolatopsis mediterranei 2142 - producer rifamycin Century table 3.

The invention relates to the microbiological industry, in particular, to the production of antibiotics, namely, rifamycin Century Rifamycin In serves as the basis for the production of semi-synthetic antibiotic rifamycin, used to treat tuberculosis, leprosy, etc.

There are several strains producers of rifamycin In: Streptomyces mediterranei ATCC 13685 with an activity of 400 µg/ml [1] Str. mediterranei ATCC 21789 activity 2300 µg/ml [2] Str. albovinaceus ATCC 12951 with an activity of 400 µg/ml [1] Str. tolypophorus B-2847 activity 250 µg/ml [3] Nocardia asiatica 2739 activity 400 μg/ml [4] Str. albovinaceus G5/A activity 5500 μg/ml [5]

The prototype of the present invention is the most active of these mutant strains of Streptomyces albovinaceus G5/A activity 5500 μg/ml to 150 h of fermentation [5]

The disadvantage of all known strains producers of rifamycin In is low active.

The aim of the invention is the obtaining of the producer strain, dia (according to modern classification Amycolatopsis) mediterranei P-84 [6] with the selection of mutants on the basis of reduced sensitivity of the biosynthesis of concentration barbitala in a fermentation medium.

The result is a new strain Amycolatpsis mediterranei P-91, high productivity biosynthesis of rifamycin B, and also a number of morphological, cultural and physiological properties. A new strain of P-91 forms 20500 mg/ml rifamycin In at 216 h, which is almost three times the productivity of the biosynthesis of the prototype strain G5/A (5500 μg/ml to 150 hours).

Strain Amycolatpsis medinerranei P-91 deposited in culture collections of the all-Union research Institute of antibiotics, number 2142. Certificate of Deposit is attached.

In tables 1 and 2 describes the cultural-morphological and physiological properties of the strains G5/A and P-91.

Substrate mycelium and soluble pigment in strain P-91 are characterized by a brown, red, yellow, brown shades, while the prototype strain G5/A, normal gray and bluish shades (environments Waxman, ISP 2, 3, 4).

In contrast to strain R-91, strain G5/A is not absorbed galactose and sucrose and weakly absorbs the raffinose. Main differences between strains are summarized in table. 3.

The invention is illustrated by the following example.

Suspension of mycelium culture Amycolatopsis mediterranei P-91, grown on agar medium, seeded liquid sowing with the Yes the rest. After 65 h of growth seed mycelium in the amount of 10% of the inoculated fermentation medium of the following composition (wt.): glucose 4,0; sucrose 9,0; soy flour 3,0; ammonium sulfate 1,1; diammonium phosphate 0,06; chalk 1,6; water the rest.

After 216 h of fermentation culture liquid accumulates 20500 mg/ml rifamycin Century

Strain Amycolatopsis mediterranei 2142 - producer rifamycin Century

 

Same patents:

The invention relates to the field of biotechnology, in particular the production of therapeutic and preventive drugs used in disorders of the gastrointestinal tract, disbacteriosis, enzyme deficiency of the digestive system, purulent infections, food allergies

The invention relates to the microbiological industry, and represents a new strain of the fungus, which can be used to produce biomass from carbohydrate-containing carbon sources such as carbohydrates (sugar), organic acids, alcohols, etc

The invention relates to the field of medical Microbiology and can be used to determine the biological activity of microorganisms

The invention relates to the microbiological industry, in particular the production of the macrolide antibiotic tylosin used in animal husbandry and veterinary medicine for the treatment of farm animals, and as a stimulator of the growth of young birds and cattle

The invention relates to medical Microbiology, namely the production of antagonistic biological products and, in particular, colibacterin

The invention relates to Microbiology, and represents a new strain of wine yeast, intended for use in the wine industry, in particular, in the production of champagne, sparkling grape and fruit wines

The invention relates to the microbiological industry, and for the producer of ubiquinone (coenzyme Q-10), having a medical purpose, for detoxicate, some of antitumor antibiotics and psychotropic drugs
The invention relates to medical Microbiology, in particular antagonists of pathogenic and conditionally pathogenic for human microflora and is a biologically active, antibiotic-resistant strain of Lactobacillus acidopilus, with pronounced antimicrobial activity against the causative agents of intestinal infectious diseases, including

The invention relates to medicine, namely to methods for determining the biological activity of drugs adaptogens

The invention relates to a new antitumor chromophore derived from cedarcide antibiotic
The invention relates to the microbiological industry, in particular the production of antibiotics

The invention relates to biotechnology and relates to a new strain of the actinomycete Streptomyces pluricolorescens isolated from the marine domain precipitation, producer of the new polypeptide antibiotic palmeranian possessing inhibitory activity against gram-positive bacteria

FIELD: biotechnology, microbiology.

SUBSTANCE: invention proposes a method for preparing exopolysaccharide by culturing microorganisms in nutrient medium containing one or more carbon source assimilated by microorganisms and caruba seeds fraction as nitrogen organic source. Applying the proposed method provides preparing exopolysaccharide eliciting improved organoleptic, sensor and visual properties. Invention can be used in building, paper, textile, cosmetic, food, oil output industry and agriculture.

EFFECT: improved preparing method.

15 cl, 4 ex

FIELD: canned food industry.

SUBSTANCE: method involves preparing fruits; adding sugar solution; providing cavitational grinding of fruits in sugar solution and separating pulp under aseptic conditions; providing cavitational grinding by dispersing under atmospheric pressure in mixture of fruits and sugar solution of mycelium produced after extracting of Mortierella zychae micromycet biomass with non-polar liquefied gas; sequentially extracting biomass with water, alkaline, water, acid, water, alkaline, and water; introducing resultant solid residue into sugar solution in an amount of about 0.06% by weight of fruits.

EFFECT: reduced consumption of power for producing of canned food, improved quality of canned food owing to improved retention of color of basic material, and increased resistance to breaking of canned food during storage.

3 ex

FIELD: food industry, confectionary industry.

SUBSTANCE: for the purpose to obtain jelly marmalade with a wide spectrum of vitamin activity and unconventional pleasant combination of organoleptic properties one should prepare the syrup by applying sugar, pectin and an aqueous extract of the mixture of baikhovi black tea, baikhovi green tea, Centaurea flowers, calendula flowers, mountain cranberry leaves, hibiscus flowers and dog rose fruit. While preparing it is necessary to supplement the syrup with citric acid, sodium lactate, "Mountain cranberry" and "Cream" aromatizing agents and a preparation obtained out of Mortierella exigua micromycete biomass by the preset technique to be further spread, formed, dried and packed as ready-to-use products.

EFFECT: higher efficiency.

FIELD: chemistry.

SUBSTANCE: invention relates to technology of glycopeptides purification. Clarified liquid containing eremomycin is compacted with sulphuretted stirol-divinylbenzene cationite, elution is carried out and neutralised eluate is applied on the column with hydrophobic stirol divinylbenzene sorbent. After washing column with water, eremomycin is displaced with solution of isopropyl alcohol with addition of acetic acid and crystallisation of target product is carried out.

EFFECT: obtaining a pure product with a high output at a high process productivity.

6 cl, 3 ex

FIELD: microbiology; medicine.

SUBSTANCE: strain Amycolatopsis orientalis subsp.eremomycini All-Russian collection of industrial microorganisms Ac-807 is eremomycin producent and can be used as source of eremomycin in medicine for treatment of severe infections.

EFFECT: increase of eremomycin output.

2 tbl, 1 ex

FIELD: biology.

SUBSTANCE: proposed strain of Nonomuraea roseoviolacea subsp carminata (Actinomadura carminata) BKIIM-S1081 is obtained as a result of multiple stage mutagenic effect of nitrimethylbiurets, methylnitrosoguanidine and gamma rays 60Co on the initial strain № All Russian collection of industrial microorganisms S-806 with subsequent extraction of mutants on media, containing streptomycin and daunorubicin as selective agents, and deposited under the number All Russian collection of industrial microorganisms S-1081. Carminomycine is obtained from biosynthesis of a strain producer, treatment of culture liquid with acetone and oxalic acid, alkalisation of the solution, extraction of antibiotic using chloroform, re-extraction of antibiotic using an aqueous buffer at pH=5.0, repeated extraction using organic solvents at pH=8.0, concentration of the extract, filtration through a neutral PTFE sorbent and extraction of antibiotic through precipitation from the solution in dichloromethane-hexane or petroleum-ether in form of a base.

EFFECT: increased output of carminomycine antibiotic, efficient in therapy of soft tissue sarcoma, lymphosarcoma, reticulosarcoma, chorionepithelioma, acute myeloblastoma and lymphoblastoma, chronic myeloid leukaemia (120 mcg in 1 ml of culture liquid).

2 cl, 1 tbl, 1 ex

Up!